181695-81-8

Basic information

• Product Name: 1-Hydroxy Valdecoxib
• Synonyms: 1-Hydroxy Valdecoxib;4-[5-(HydroxyMethyl)-3-phenyl-4-isoxazolyl]-benzenesulfonaMide;4-(5-(hydroxyMethyl)-3-phenylisoxazol-4-yl)benzenesulfonaMide;Parecoxib SodiuM IMpurity R
• CAS NO: 181695-81-8
• Molecular Formula: C₁₆H₁₄N₂O₄S
• Molecular Weight: 330.35836
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics, Heterocycles, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 181695-81-8.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 567.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.383±0.06 g/cm3(Predicted)
• PKA: 9.83±0.10(Predicted)
• CAS DataBase Reference: 1-Hydroxy Valdecoxib(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Hydroxy Valdecoxib(181695-81-8)
• EPA Substance Registry System: 1-Hydroxy Valdecoxib(181695-81-8)

Safety Data

• Hazardous Substances Data: 181695-81-8(Hazardous Substances Data)

Usage

Uses

Valdecoxib metabolite.

Upstream product

• 181696-34-4 4-[5-chloromethyl-3-phenylisoxazol-4-yl]benzenesulfonamide 
• 181695-72-7 valdecoxib 
• 451-40-1 phenyl benzyl ketone 
• 952-06-7 deoxybenzoin oxime 
• 181696-73-1 3,4-diphenyl-4-hydrido-5-hydroxy-5-methylisoxazole 
• 509074-26-4 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonyl chloride 

Downstream Products

• 869012-64-6 toluene-4-sulfonic acid 4-(4-{[bis-(4-methoxy-phenyl)-phenyl-methyl]-sulfamoyl}-phenyl)-3-phenyl-isoxazol-5-ylmethyl ester 
• 198471-84-0 N-[[4-(5-propoxymethyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]propanamide 
• 181696-37-7 4-(5-(methoxymethyl)-3-phenylisoxazol-4-yl)benzenesulfonamide 

Relevant articles and documents

COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR

The present invention provides a combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor for the treatment or prevention of pain or nociception.

Substituted isoxazoles for the treatment of inflammation

A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula (III) wherein R7 is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxylalkyl, lower alkoxycarbonylalkyl, lower alkoxyalkyl, lower carboxyalkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxyalkyl, lower aryl (hydroxylalkyl), lower carboxyaryloxyalkyl, lower alkoxycarbonylaryloxyalkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower aralkyl; and wherein R8 is one or more radicals independently selected from hydrido, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.

Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor

The present invention provides a method for the treatment or prophylaxis of COX-2-mediated conditions in patients who are at risk of developing thromboembolic events which comprises administering to said patient a therapeutically or prophylactically effective amount of a COX-2 selective inhibitor and a cardiovascular protective amount of a thromboxane inhibitor, as well as compositions therefor.